Galapagos Q1 Results Detail Gilead Partnership for Autoimmune Drug, $1.675B Upfront Split
Summary
Galapagos NV reported its first quarter 2026 financial results and provided a significant business update, detailing its collaboration agreement with Gilead Sciences (GILD) regarding Gilead's acquisition of Ouro Medicines. Galapagos will assume Ouro's operating assets and personnel, and co-develop gamgertamig (OM336), a clinical-stage T-cell engager for autoimmune diseases that has received Fast Track and Orphan Drug Designation. The transaction, expected to close in Q2 2026, includes a $1.675 billion upfront payment and up to $500 million in contingent milestones, both to be split equally between Galapagos and Gilead. This strategic partnership brings a promising late-stage asset into Galapagos' pipeline, significantly de-risking its development with shared costs. The substantial cash inflow from the upfront payment and the increased financial flexibility, including $500 million for independent business development and up to $150 million for share repurchases, are highly positive for Galapagos' valuation and future strategy. Traders will monitor the closing of the Gilead/Ouro transaction and the progress of gamgertamig into registrational studies, expected as early as 2027.
At the time of this announcement, GLPG was trading at $28.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $24.74 to $37.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.